Jean B Nachega, MD, PhD, MPH,

Associate Professor, Infectious Diseases and Microbiology

Associate Professor, Epidemiology

Contact

R-znvy: woa61@cvgg.rqh
Primary Phone: 967-179-6044


Personal Statement

Jean Nachega, MD, PhD, MPH, FRCP: Associate Professor of Medicine,
Infectious Diseases, Microbiology and Epidemiology, at Graduate School of
Public Health, Pittsburgh University. Dr Nachega is also an Adjunct Associate
Professor of Epidemiology and International Health at Johns Hopkins Bloomberg School of Public Health; and Professor Extraordinary of Medicine at Stellenbosch University, Cape Town, South Africa. He received his training in Belgium (University of Louvain), UK (London School of Hygiene & Tropical Medicine), USA (Johns Hopkins University & Harvard University). He has over 25 year-experience in patient care, teaching, designing and implementing HIV/AIDS and Tuberculosis studies or programs funded by NIH/NIAID, PEPFAR, EDCTP, and Wellcome Trust. He authored more than 200 peer-reviewed publications including in top-tier journals such as The Lancet, The New England Journal of Medicine, JAMA, Clinical Infectious Diseases and Annals of Internal Medicine. He is an ad hoc consultant at WHO, CDC, Bill and Melinda Gates Foundation, as well as a member of Academy of Sciences of South Africa (ASSAf) and African Academy of Sciences (AAS)
 


Education

1985 \ Facultes Universitaires Notre Dame de la Paix, Namur, Belgium\ BS (Cum Laude)
1989 \ University Catholic of Louvain, Brussels, Belgium \ MD (Cum Laude)
1999 \ Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA \ MPH
2000 \ London School of Hygiene & Tropical Medicine, London, UK \ DTM&H
2008 \ University of Cape Town, South Africa \ PhD
2010 \ Harvard School of Public Health, Boston, MA, USA \ John  McGoldrick Fellow in Biostat in AIDS Research, Decision Analysis and Health Economics


Teaching

• Primary Instructor: A) EPIDEM2160, Infectious Diseases Epidemiology (Two Credits); B) EPIDEM2166, Global Control of Tuberculosis & HIV, SPRING Term (One Credit); C) EPIDEM2162, Infectious Diseases & Global Health, FALL Term (Two Credits).


Selected Publications

1: Ntoumi F, Nachega JB, Aklillu E, Chakaya J, Felker I, Amanullah F, Yeboah-Manu D, Castro KG, Zumla A. World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis. Lancet Infect Dis. 2022 Apr;22(4):442-444. doi: 10.1016/S1473-3099(22)00142-6. Epub 2022 Mar 3. PMID: 35248166

 

2: Nachega JB, Sam-Agudu NA, Machekano RN, Rabie H, van der Zalm MM, Redfern A, Dramowski A, O'Connell N, Pipo MT, Tshilanda MB, Byamungu LN, Masekela R, Jeena PM, Pillay A, Gachuno OW, Kinuthia J, Ishoso DK, Amoako E, Agyare E, Agbeno EK, Martyn-Dickens C, Sylverken J, Enimil A, Jibril AM, Abdullahi AM, Amadi O, Umar UM, Sigwadhi LN, Hermans MP, Otokoye JO, Mbala-Kingebeni P, Muyembe-Tamfum JJ, Zumla A, Sewankambo NK, Aanyu HT, Musoke P, Suleman F, Adejumo P, Noormahomed EV, Deckelbaum RJ, Fowler MG, Tshilolo L, Smith G, Mills EJ, Umar LW, Siedner MJ, Kruger M, Rosenthal PJ, Mellors JW, Mofenson LM; African Forum for Research and Education in Health (AFREhealth) COVID-19 Research Collaboration on Children and Adolescents. Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African JAMA Pediatr. 2022 Jan 19:e216436. doi: 10.1001/jamapediatrics.2021.6436. Online ahead of print. PMID: 35044430

 

3: Sam-Agudu NA, Quakyi NK, Masekela R, Zumla A, Nachega JB. Children, and adolescents in African countries should also be vaccinated for COVID-19. BMJ Glob Health. 2022 Feb;7(2):e008315. doi: 10.1136/bmjgh-2021-008315. PMID: 35144923

 

4: Nachega JB, Sam-Agudu NA, Mellors JW, Zumla A, Mofenson LM. Scaling Up Covid-19 Vaccination in Africa - Lessons from the HIV Pandemic. N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103313. Epub ahead of print. PMID: 33789005.

 

5: Nachega JB, Maeurer M, Sam-Agudu NA, Chakaya J, Katoto PDM, Zumla A. Bacille Calmette-Guérin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection - Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base. Int J Infect Dis. 2021 Mar 29:S1201-9712(21)00279-4. doi: 10.1016/j.ijid.2021.03.060. Epub ahead of print. PMID: 33794380; PMCID: PMC8006492.

 

6: Nachega JB, Kapata N, Sam-Agudu NA, Decloedt EH, Katoto PDMC, Nagu T, Mwaba P, Yeboah-Manu D, Chanda-Kapata P, Ntoumi F, Geng EH, Zumla A. Minimizing the impact of the triple burden of COVID-19, tuberculosis and HIV on health services in sub-Saharan Africa. Int J Infect Dis. 2021 Mar 20:S1201-9712(21)00256-3. doi: 10.1016/j.ijid.2021.03.038. Epub ahead of print. PMID: 33757874; PMCID: PMC7980520.

 

7: Nachega JB, Sam-Agudu NA, Masekela R, van der Zalm MM, Nsanzimana S, Condo J, Ntoumi F, Rabie H, Kruger M, Wiysonge CS, Ditekemena JD, Chirimwami RB, Ntakwinja M, Mukwege DM, Noormahomed E, Paleker M, Mahomed H, Tamfum JM, Zumla A, Suleman F. Addressing challenges to rolling out COVID-19 vaccines in African countries. Lancet Glob Health. 2021 Jun;9(6):e746-e748. doi:10.1016/S2214-109X(21)00097-8. Epub 2021 Mar 10. PMID: 33713633; PMCID: PMC7946417.

 

8: Nachega JB, Borre ED, Dowdy DW, Chanda-Kapata P, Cleary S, Geng EH. Cost- effectiveness of universal HIV testing and treatment: where next? Lancet Glob Health. 2021 May;9(5):e573-e574. doi: 10.1016/S2214-109X(21)00089-9. Epub 2021 Mar 12. PMID: 33721567.

 

9. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012 Oct 23;26(16):2039-52. doi: 10.1097/QAD.0b013e328359590f. PMID: 22951634

 

10. Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010 Jan 5;152(1):18-25. doi: 10.7326/0003-4819-152-1-201001050-00006. PMID: 20048268

 

11. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.  Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007 Apr 17;146(8):564-73. doi: 10.7326/0003-4819-146-8-200704170-00007

Jean B Nachega